stockrow
Saturday 7 November 2026
Export AZTR’s income statement to Excel — free account
Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- EPS
- +85.3%
- Free cash flow
- −19.6%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow AZTR
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(215.04%) | (230.65%) | (158.71%) | (256.67%) | |
| (157.91%) | (176.92%) | (131.02%) | (190.69%) | ||
ROIC |
(796.07%) | (395.49%) | (1,717.97%) | (1,272.49%) | |
Return on Tangible Assets |
(1,107.39%) | (438.23%) | (121.29%) | (190.29%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(27.03) | (23.40) | (6.98) | (5.90) | |
Free Cash Flow |
(11.13) | (11.41) | (10.83) | (11.39) | |
Capital Expenditures |
(0.21) | (0.18) | (0.20) | (0.28) | |
| Other line items | |||||
Cash ROIC |
(302.42%) | (194.35%) | (52.74%) | (80.96%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,432.60) | (1,424.25) | (1,204.12) | (1,154.04) | |
Operating CF/Net income |
0.98 | 1.02 | 0.90 | 0.90 | |
Depreciation/Fixed assets |
0.79 | 0.83 | 2.03 | 2.01 | |
Capex/Depreciation |
(0.47) | (0.40) | (0.18) | (0.26) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(26.51) | (23.03) | (6.85) | (5.75) | |
Capex per Share |
(0.52) | (0.38) | (0.13) | (0.14) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026